Gene:
KRT3
keratin 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  cytokeratin 3; keratin, type II cytoskeletal 3
Alternate Symbols:  CK3; K3
PharmGKB Accession Id: PA30228

Details

Cytogenetic Location: chr12 : q13.13 - q13.13
GP mRNA Boundary: chr12 : 53183469 - 53189892
GP Gene Boundary: chr12 : 53180469 - 53199892
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

LinkOuts

Entrez Gene:
3850
OMIM:
122100
148043
UCSC Genome Browser:
NM_057088
RefSeq RNA:
NM_057088
RefSeq Protein:
NP_476429
RefSeq DNA:
AC_000055
AC_000144
NC_000012
NG_008350
NT_029419
NW_001838059
NW_925395
UniProtKB:
K2C3_HUMAN (P12035)
Ensembl:
ENSG00000186442
GenAtlas:
KRT3
GeneCard:
KRT3
MutDB:
KRT3
ALFRED:
LO045951Y
HuGE:
KRT3
Comparative Toxicogenomics Database:
3850
ModBase:
P12035
HumanCyc Gene:
HS10582
HGNC:
6440

Common Searches